Dear Editor, Arsenic trioxide (As 2 O 3 ) is a standard medication for relapsed acute promyelocytic leukemia (APL). However, high blood arsenic levels lead to potentially fatal arrhythmias. As 2 O 3 is renal-excreted and considered contraindicated in renal failure.
Dear Editor, Arsenic trioxide (As 2 O 3 ) is a standard medication for relapsed acute promyelocytic leukemia (APL). However, high blood arsenic levels lead to potentially fatal arrhythmias. As 2 O 3 is renal-excreted and considered contraindicated in renal failure.
A 42-year-old man was referred for treatment of APL in first relapse, presenting with pancytopenia, impaired renal function, and septicemia. He was treated with all-trans retinoic acid (ATRA, 45 mg/m 2 /day) and oral As 2 O 3 (10 mg/ day) [1] . Progressive renal function derangement developed, necessitating reduction of oral As 2 O 3 to 5 mg/day. On the third day, the leukocyte count increased to 8.9×10 9 /L, associated with bilateral pulmonary infiltrates. Features were consistent with the APL differentiation syndrome, which with the underlying septicemia led to anuric acute renal failure. ATRA was stopped. Idarubicin (6 mg/m 2 /day×5), dexamethasone (12 mg/day×7), and alternate daily hemodialysis were administered. Oral As 2 O 3 at 5 mg was given after each hemodialysis and was stopped after 9 days. At 4 weeks, marrow examination confirmed complete remission. He remained anuric, and hemodialysis was continued. Oral As 2 O 3 was re-commenced at 2 mg after each hemodialysis. Two months later, continuous ambulatory peritoneal dialysis (CAPD) was started. A maintenance regimen for APL, comprising oral As 2 O 3 (5 mg/day) and ATRA (20 mg twice daily) [2, 3] , given 2 weeks every 2 months, was administered. At 6-month follow-up, he remained in remission and was negative for the PML-RARA fusion gene characteristic of APL. No cardiac arrhythmias were observed at any time.
Serum elemental arsenic levels were assayed by inductively coupled plasma mass spectrometry [3, 4] , on blood samples sent for creatinine measurement. At 4 days, there was a sudden increase of arsenic levels, as the cellular and third-space compartments became saturated and anuria prevented arsenic excretion (Fig. 1a) . The arsenic level peaked at 4,240 nmol/L, outside the therapeutic range of 500-2,000 nmol/L typical of oral As 2 O 3 . The commencement of hemodialysis and cessation of oral As 2 O 3 resulted in a fall of arsenic levels parallel to those of creatinine. After oral As 2 O 3 was re-commenced, arsenic levels gradually increased to the therapeutic range (Fig. 1b) . As arsenic clearance in oral As 2 O 3 therapy during CAPD had been documented previously [3] , arsenic assays were not performed after peritoneal dialysis was started.
As 2 O 3 is a key medication for patients with relapsed APL. Intravenous (i.v.) As 2 O 3 , used in most reports, may lead to lethal arrhythmias due to QT prolongation, which is directly proportional to blood arsenic levels [5] . Because i.v. As 2 O 3 leads to a rapid surge of blood arsenic levels, arrhythmia related to QT prolongation is an important adverse effect. Oral As 2 O 3 is slowly absorbed and results in lower blood arsenic levels. Its bioavailability, estimated by area-under-the-curve pharmacokinetically, is comparable to that of i.v. As 2 O 3 [6] . Hence, oral As 2 O 3 has the same efficacy, but little risk of arrhythmia [5] . In one previous report, blood arsenic levels after i.v. As 2 O 3 were measured in an APL patient on hemodialysis [7] . The peak level was 6,450 nmol/L, a toxic level that led to termination of i.v. As 2 O 3 therapy. It was concluded that i.v. As 2 O 3 was contraindicated in renal failure [7] . In our case, the sudden increase in blood arsenic levels was related to an unanticipated acute renal failure. Timely cessation of oral As 2 O 3 and institution of hemodialysis prevented further increases in arsenic levels. Subsequently, with careful dose adjustment and meticulous monitoring, oral As 2 O 3 was safely administered during hemodialysis. The blood arsenic levels were also kept within the therapeutic range. We have also previously demonstrated the safety of oral As 2 O 3 during CAPD. Therefore, patients on renal replacement therapy are still eligible for oral As 2 O 3 treatment. With the re-commencement of oral arsenic trioxide on day 42, there was a gradual increase of arsenic levels back to the therapeutic range. Arsenic levels also varied in parallel with creatinine levels during hemodialysis and had remained within the therapeutic range
